Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

10%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

5(62.5%)

Phase 2

2(25.0%)

Phase 4

1(12.5%)

8Total

Phase 1(5)

Phase 2(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT06997276Phase 1Recruiting

Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib

Role: lead

NCT07171619Phase 1Completed

Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat

Role: lead

NCT06251310Phase 1Recruiting

SW-682 in Advanced Solid Tumors

Role: lead

NCT07170644Phase 2Active Not Recruiting

A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

Role: lead

NCT05041036Unknown

Individual Patient Compassionate Use of Nirogacestat

Role: lead

NCT07176689Phase 4Recruiting

Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

Role: lead

NCT05028166Unknown

Individual Patient Compassionate Use of Mirdametinib

Role: lead

NCT07279233Phase 1Completed

To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants

Role: lead

NCT03962543Phase 2Active Not Recruiting

MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

Role: lead

NCT07259330Phase 1Completed

To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants

Role: lead

All 10 trials loaded